This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by ZHANG, H.-J. Articles by ROBERTSON, R. P. Search for Related Content PubMed PubMed Citation Articles by ZHANG, H.-J. Articles by ROBERTSON, R. P.

Somatostatin and Epinephrine Decrease Insulin Messenger Ribonucleic Acid in HIT Cells through a Pertussis Toxin-Sensitive Mechanism^*

Diabetes Center and the Division of Endocrinology and Metabolism, Department of Medicine, University of Minnesota Medical School Minneapolis, Minnesota 55455

Address requests for reprints and all correspondence to: R. Paul Robertson, M.D., The Diabetes Center, Box 101 University of Minnesota Health Center, University of Minnesota, Minneapolis, Minnesota 55455.

Abstract

The sites of action for somatostatin and epinephrine to inhibit insulin secretion have been reported to be exclusively in the exocytotic pathway. We used HIT cells, a clonal line of β-cells, to examine whether these hormones might have as yet undescribed, nonexocytotic effects on insulin messenger RNA levels. We observed that both somatostatin and epinephrine not only inhibit insulin secretion (53 ± 2% and 50 ± 2% of control, respectively) but also decrease insulin mRNA levels (54 ± 5% and 66 ± 5% of control, respectively) and insulin content in HIT cells (61 ± 2% and 51 ± 1% of control, respectively). The latter two effects are discernible by 24 h, maximal by 48 h, and are prevented by preincubation of HIT cells with pertussis toxin. These new observations suggest that somatostatin and epinephrine negatively modulate insulin availability through a guanine nucleotide binding protein-mediated step in insulin synthesis before the exocytotic pathway. This general mechanism may allow these two hormones to serve as more long-term regulators of insulin availability in distinction to their shorter term and more readily reversible inhibitory effects on the exocytotic pathway. (Endocrinology 129: 2409–2414, 1991)

Footnotes

^* Supported by NIH Grants R01-DK-38325 (to R. P. R.) and F32-DK-08482 (to J.B.R.)

Received January 1, 1991.